Torii Pharmaceutical Co (4551) AI Stock Analysis

• Market Cap: $177.83B
• Dividend Yield: 1.9%
• Average Volume (3M): 113.07K
• Price to Earnings (P/E): 32.0
• Beta (1Y): 0.71
• Revenue Growth: 9.56%
• EPS Growth: 5.09%
• Country: JP
• Employees: 592
• Sector: Healthcare
• Sector Strength: 46
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 197.61
• Shares Outstanding: 28,800,000
• 10 Day Avg. Volume: 55,520
• 30 Day Avg. Volume: 113,070
• PEG Ratio: 1.23
• Price to Book (P/B): 0.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 38.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: ¥6,825.00 ▲(7.82%Upside)

Torii Pharmaceutical Co's stock is supported by strong financial performance with consistent revenue growth and a robust balance sheet. However, technical indicators highlight an overbought situation, and the valuation suggests a relatively high price, balancing the overall stock score.

Torii Pharmaceutical Co Business Overview & Revenue Model

Company Description

Torii Pharmaceutical Co (4551) is a Japanese pharmaceutical company engaged in the research, development, manufacture, and sale of pharmaceutical products. The company focuses on therapeutic areas including renal diseases, skin diseases, and allergy-related conditions. Torii Pharmaceutical is committed to providing high-quality pharmaceutical solutions and improving healthcare outcomes.

How the Company Makes Money

Torii Pharmaceutical Co makes money primarily through the sale of its pharmaceutical products, which are developed in-house or through collaborations with other pharmaceutical companies. The company generates revenue from both domestic and international markets, with a significant portion of income derived from its core therapeutic areas. Additionally, Torii Pharmaceutical may engage in strategic partnerships and licensing agreements, which can provide additional revenue streams through royalties or shared profits from co-developed products. The company also invests in research and development to innovate and expand its product portfolio, which can lead to new revenue opportunities.

Torii Pharmaceutical Co Financial Statement Overview

Summary

Torii Pharmaceutical Co demonstrates strong financial health with consistent revenue growth and solid profitability margins. The balance sheet is robust with minimal debt, and cash flow has shown improvements despite some past volatility. Overall, the company's financials provide a solid foundation for future growth.

Income Statement

Torii Pharmaceutical Co shows a strong financial performance with consistent revenue growth, evidenced by a 10.6% increase in 2024 and a 11.7% increase in 2023. The gross profit margin is stable, averaging around 40% over the last few years. The net profit margin also shows a positive trend, with a rise from 7.5% in 2021 to 8.3% in 2024, indicating improving profitability. The EBIT and EBITDA margins are healthy, showing operational efficiency. However, the gross profit in 2024 dropped slightly compared to 2023, which could be a sign of increased cost pressures.

Balance Sheet

The company maintains a solid financial position with a low debt-to-equity ratio of 0.004 in 2024, showcasing minimal leverage. The equity ratio is robust at 86.4%, highlighting a strong reliance on equity financing. Return on equity (ROE) is relatively stable, standing at 4.1% in 2024, reflecting moderate profitability from shareholders' perspective. The company’s substantial cash reserves further enhance its financial stability, although a decrease in cash reserves was noted over the recent years.

Cash Flow

Torii Pharmaceutical Co's cash flow situation has improved, with a positive free cash flow reported in 2024 after a negative figure in 2023. The operating cash flow to net income ratio is positive, indicating efficient cash generation relative to net income. The free cash flow to net income ratio also supports this positive outlook. However, the company experienced negative operating cash flows in certain years, suggesting potential volatility in cash generation. Capital expenditure is consistently low, which may limit future growth investments.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
60.43B	54.64B	48.89B	46.99B	41.70B
	Gross Profit
24.42B	24.79B	23.38B	24.34B	21.74B
	EBIT
6.80B	5.04B	5.54B	4.66B	4.74B
	EBITDA
7.21B	5.83B	5.97B	5.05B	4.69B
	Net Income Common Stockholders
5.04B	4.12B	3.94B	3.37B	3.50B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
43.30B	44.00B	58.91B	65.57B	70.10B
	Total Assets
140.66B	133.43B	133.69B	130.81B	126.03B
	Total Debt
429.00M	244.00M	524.00M	486.00M	294.00M
	Net Debt
-2.89B	-4.76B	-19.90B	-26.89B	-31.28B
	Total Liabilities
19.13B	13.30B	14.46B	13.80B	10.94B
	Stockholders Equity
121.53B	120.13B	119.22B	117.01B	115.09B
Cash Flow		Free Cash Flow
3.49B	-3.34B	2.14B	-530.00M	-3.85B
	Operating Cash Flow
3.64B	-3.12B	2.42B	-156.00M	-3.44B
	Investing Cash Flow
-3.57B	-3.78B	-13.68B	-1.50B	7.63B
	Financing Cash Flow
-3.94B	-3.83B	-1.70B	-1.55B	-1.43B

Torii Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6330.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4551, the sentiment is Positive. The current price of 6330 is below the 20-day moving average (MA) of 6335.50, above the 50-day MA of 5684.10, and above the 200-day MA of 4653.98, indicating a neutral trend. The MACD of 138.63 indicates Positive momentum. The RSI at 76.96 is Negative, neither overbought nor oversold. The STOCH value of 7.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4551.

Torii Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4553	81 Outperform	¥145.33B	7.66	11.38%	2.71%	13.89%	17.38%
4547	75 Outperform	$173.51B	14.99	5.47%	2.19%	16.87%	11.20%
4521	74 Outperform	$138.46B	10.52	9.44%	3.90%	30.52%	71.75%
4887	69 Neutral	¥185.40B	10.08		2.90%	-3.69%	76.69%
4534	67 Neutral	€100.11B	18.35	4.35%	2.72%	5.31%	90.37%
4551	65 Neutral	$177.83B	32.03	4.56%	1.90%	9.56%	5.09%
Sector *	53 Neutral	$5.22B	3.33	-44.36%	7.55%	16.78%	-0.12%